Understanding what goes wrong in cells that leads to malignant rhabdoid tumours
Unravelling the impact of SMARCB1 loss on the chromatin landscape in malignant rhabdoid tumor to identify novel therapeutic opportunities
Investigating a newly discovered gene to improve our understanding of Wilms tumour
Epigenetic deregulation of splicing in childhood renal malignancies
Understanding the biology of malignant rhabdoid tumours to develop targeted treatments
Improved therapeutic targeting in malignant rhabdoid tumours using discovery proteomics analysis
Developing a test to help treat leukaemia that has spread to the brain
Developing leukaemic biomarkers to enable personalised CNS-directed therapy
Understanding the order of genetic changes that lead to Wilms tumour to improve treatment
Ordering of driver mutations in bilateral Wilms’ tumour
Discovering the differences between craniopharyngiomas that regrow after treatment and those that don't
Molecular profiling of relapsing craniopharyngioma
Helping to develop research into antibody treatment
Investigation of ganglioside-specific receptor expression by tumour-infiltrating immune cells
Improving our understanding of how chemotherapy works in hepatoblastoma
Analysis of genome-wide 5-hydroxymethylcytosine patterns in human hepatoblastoma tumours during chemotherapy treatment
Improving our understanding of leukaemia that has spread throughout the body
Defining the tumour microenvironment in extramedullary acute leukaemia